Compare Quest Diagnostics Inc (DGX) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NetEase Inc — how do they compare? Quest Diagnostics Inc trades at $231.12 (market cap $25.48B), while NetEase Inc trades at $125.31 (market cap $76.09B). The key difference: NetEase Inc is far larger — about 3× Quest Diagnostics Inc's market cap, and NetEase Inc pays the higher dividend (2.45%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and NetEase Inc for 74 Days on average.
| DGX | NTES | |
|---|---|---|
Market Cap | $25.48B | $76.09B |
Volume | 941,866 | 486,447 |
Sector | Health | Technology |
52-Week High | $247.45 | $152.85 |
52-Week Low | $173.49 | $109.26 |
Typical Hold Time | 56 Days | 74 Days |
Enterprise Value | $31.23B | $51.81B |
Dividend Yield | 1.49% | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
NetEase (NTES) trades at $120.61, up 1.29% with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $112.63B revenue and 27.88% net margin in 2025, though recent quarterly earnings show volatility with two misses in the last three quarters. Analyst consensus remains strongly bullish with 82% buy ratings and a $168 price target representing 39% upside potential.
The investment case balances strong profitability and cash generation against earnings volatility and competitive pressures. Key opportunities include consistent revenue growth and attractive valuation multiples, while risks center on gaming market competition and China regulatory environment. The stock presents value for long-term investors given the significant discount to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
